Wang Yongzhong, Yu Li, Han Limei, Sha Xianyi, Fang Xiaoling
Department of Pharmaceutics, School of Pharmacy, Fudan University, Shanghai 200032, PR China.
Int J Pharm. 2007 Jun 7;337(1-2):63-73. doi: 10.1016/j.ijpharm.2006.12.033. Epub 2006 Dec 28.
A significant obstacle for successful chemotherapy with paclitaxel (PTX) is multidrug resistance (MDR) in tumor cells. Micelles and mixed micelles were prepared from Pluronic block copolymer P105 or L101 as PTX delivery systems for overcoming MDR. Both micelle systems were covalently modified with the targeting agent folic acid to recognize and bind a variety of tumor cells via their surface-overexpressed folate receptor. There was an increased level of uptake of folate-conjugated micellar PTX (i.e. FOL-P105/PTX, FOL-PL/PTX) compared to plain micellar PTX (i.e. P105/PTX, PL/PTX) in human breast cancer MDR cell sublines, MCF-7/ADR, and the uptake of folate-conjugated micellar PTX could be inhibited by free folic acid, which suggested that the level of uptake could be mediated by the folate receptor. The cytotoxicity of folate-conjugated micellar PTX in the MDR cell culture model was much higher compared with plain micellar PTX or free PTX, and the plain micellar PTX also has higher cytotoxicity than free PTX. Overall, the MDR cells are more susceptible to the cytotoxic effects of Pluronic micellar PTX than their parental cells. The introduction of folic acid into P105 or PL mixed micelles enhanced the cell-killing effect by active internalization. Increased internalization explained the improved cytotoxicity of the FOL-micellar PTX to tumor cells. We suggest that the combined mechanisms of folate-mediated active internalization and Pluronic-mediated overcoming MDR be beneficial in treatment of MDR solid tumors by targeting delivery of micellar PTX into the tumor cells where folate receptor is frequently overexpressed, reducing accumulation of micellar PTX in other tissues or organs and further reducing side effects and toxicities of the drug.
紫杉醇(PTX)化疗成功的一个重大障碍是肿瘤细胞中的多药耐药性(MDR)。以普朗尼克嵌段共聚物P105或L101制备胶束和混合胶束作为PTX递送系统以克服多药耐药性。两种胶束系统均用靶向剂叶酸进行共价修饰,以通过其表面过表达的叶酸受体识别并结合多种肿瘤细胞。与普通胶束PTX(即P105/PTX、PL/PTX)相比,叶酸共轭胶束PTX(即FOL-P105/PTX、FOL-PL/PTX)在人乳腺癌多药耐药细胞亚系MCF-7/ADR中的摄取水平有所增加,并且游离叶酸可抑制叶酸共轭胶束PTX的摄取,这表明摄取水平可能由叶酸受体介导。在多药耐药细胞培养模型中,叶酸共轭胶束PTX的细胞毒性比普通胶束PTX或游离PTX高得多,并且普通胶束PTX的细胞毒性也高于游离PTX。总体而言,多药耐药细胞比其亲代细胞对普朗尼克胶束PTX的细胞毒性作用更敏感。将叶酸引入P105或PL混合胶束中可通过主动内化增强细胞杀伤作用。内化增加解释了FOL-胶束PTX对肿瘤细胞的细胞毒性提高。我们认为,叶酸介导的主动内化和普朗尼克介导的克服多药耐药性的联合机制有利于通过将胶束PTX靶向递送至叶酸受体经常过表达的肿瘤细胞来治疗多药耐药实体瘤,减少胶束PTX在其他组织或器官中的积累,并进一步降低药物的副作用和毒性。